When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
CYAD - Celyad up on advancement of CAR-T candidate CYAD-211
Celyad SA
The FDA has signed off on Celyad Oncology SA's (NASDAQ:CYAD) IND for a Phase 1 clinical trial evaluating lead off-the-shelf short hairpin RNA-based allogeneic CAR-T candidate CYAD-211.
More news on: Celyad Oncology SA, Healthcare stocks news, Stocks on the move,